Summary:
Metroplex Clinical Research Center is conducting a randomized, double-blind trial assessing the impact of Methotrexate discontinuation on the efficacy of subcutaneous Tocilizumab and Methotrexate therapy.
Qualified Participants Must:
• 18 years or age or older
• Be on at least 15 mg/week of Methotrexate for at least 24 weeks, and on a stable dose for at least 6 weeks
• Not have previously used Actemra
• Have no history of cancer
Qualified Participants May Receive:
Study drug and procedures at no cost and $75 per each completed visit.